San Antonio Breast Cancer Syposium
The 40th anniversary of the San Antonio Breast Cancer Symposium was attended by approximately 8000 healthcare professionals and featured presentations ranging from basic science to preliminary clinical trials and new standards of care. Below is a summary of key presentations featured at the press conferences.
Older patients with hormone receptor–positive, HER2-negative, metastatic breast cancer derive similar benefit as younger patients treated with CDK4/6 inhibitors as part of initial endocrine therapy, according to a pooled analysis of registration trials presented at the 2017 San Antonio Breast Cancer Symposium.
Results 1 - 2 of 2